- Home
- SUPV vs CSTL Comparison
SUPV vs CSTL Comparison
Compare SUPV & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPV | CSTL |
|---|---|---|
| Founded | 1887 | 2007 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 722.8M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SUPV | CSTL |
|---|---|---|
| Price | $9.01 | $31.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $13.00 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 397.5K | 390.6K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | $86.20 | $2.42 |
| Revenue Next Year | $25.12 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $4.54 | $17.72 |
| 52 Week High | $13.55 | $44.28 |
Technical Indicators
Market Signals| Indicator | SUPV | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 74.87 |
| Support Level | N/A | $22.67 |
| Resistance Level | N/A | $34.97 |
| Average True Range (ATR) | 0.00 | 1.45 |
| MACD | 0.00 | 0.55 |
| Stochastic Oscillator | 0.00 | 89.62 |
Price Performance
Historical ComparisonAbout SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, and Asset Management and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.